Samsung BioLogics will build a large-scale, fourth bioproduction plant at its existing site in Incheon Songdo, South Korea that will cement its position as the world’s largest contract development and manufacturing player in the biologics sector.
Construction of the new facility is part of the South Korean group's long-term strategy to maximize operational efficiency and scale...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?